<DOC>
	<DOCNO>NCT02914158</DOCNO>
	<brief_summary>The objective study compare curative effect patient age 35 hormone receptor positive breast cancer high recurrent risk factor include large tumor metastatic lymph node randomize ovarian function suppression ( OFS ) plus aromatase inhibitor OFS plus tamoxifen adjuvant endocrine therapy , explore difference curative effect different subtypes provide direct evidence treatment young breast cancer patient .</brief_summary>
	<brief_title>Adjuvant Ovarian Suppression Plus Aromatase Inhibitor Tamoxifen Young Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Signed informed consent ; 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ; 3 . Patients pathologically diagnose hormone receptor positive invasive breast cancer : immunohistochemistry ER positive ( ≥1 % ) ; 4 . Premenopausal patient age ≤35 year ( least menstruate prior 3 month , assess menstruation situation chemotherapy ) ; 5 . No distant metastasis ; 6 . Clinical stage ( TNM ) meet least one condition follow : T≥2cm least one region regional lymph node metastasis ( include micrometastases ) ; 7 . Patients must undergo surgery ( neo ) adjuvant chemotherapy , target therapy , radiotherapy ( necessary ) accord Chinese AntiCancer Association guideline specification version 2015 diagnosis treatment breast cancer ; 8 . Indexes hematology biochemistry conform follow standard : HGB≥10g/dl , WBC≥4,000/mm3 , PLT≥100,000/mm3 , GOT , GPT , ALP≤2xULN , TBIL , DBIL , CCr≤1.5xULN . 1 . Pregnant lactate woman woman childbearing potential reject contraceptive measure ; 2 . History organ transplantation ( include autologous bone marrow transplantation peripheral stem cell transplantation ) ; 3 . Concurrent malignancy history nonbreast malignancy within 5 year prior study entry , except curatively treat basal cell squamous cell carcinoma skin , carcinoma situ cervix ; peripheral nervous system disorder cause disease history obvious mental central nervous system disorder ; 4 . Prior use neoadjuvant chemotherapy definite diagnosis ; 5 . Nervous system disorder cause disease obvious mental disorder , would affect patient right consent compliance , make patient critical condition ; 6 . Serious hepatopathy ( e.g. , cirrhosis , etc . ) , nephropathy , respiratory illness , digestive illness poorly control diabetes ; 7 . Cardiac illness obvious abnormal EKG clinical symptom , namely congestive heart failure , coronary atherosclerotic heart disease obvious symptom , arrhythmia difficult control drug , history myocardial infarction within 12 month prior study entry class III/IV cardiac function ; 8 . Concurrent treatment another investigational trial ; 9 . Sensitivity contraindication study medication .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>ovarian function suppression ( OFS )</keyword>
	<keyword>aromatase inhibitors（AIs）</keyword>
	<keyword>tamoxifen（TAM）</keyword>
</DOC>